Navigation Links
Biomarkers May Predict Aggressiveness of Prostate Cancer
Date:5/5/2009

Cancer expert is wary of finding, however

TUESDAY, May 5 (HealthDay News) --Three molecules associated with prostate cancer might provide the long-sought markers that could discern which tumors are life-threatening and need aggressive treatment, a new study indicates.

The currently hot debate about the value of screening for early detection of prostate cancer hinges on the fact that the cancer is usually so slow-growing that there is no lifesaving benefit from treatment such as surgery, which can cause impotence and incontinence. Recent studies in the United States and Europe found at best limited benefit from routine prostate cancer screening, and new guidelines from the American Urological Association say that many men do not need annual screening tests.

As yet, there are no established markers to distinguish which prostate cancers grow fast enough to require such treatment. The new study, published in the May 5 issue of the Annals of Internal Medicine, identifies three such markers.

"We're not trying to say these are the only markers," said study author Dr. John Concato, a professor of medicine at Yale University and director of the clinical epidemiological research for the Veterans Affairs Connecticut Healthcare System. "This is a proof of principle."

Measuring levels of the markers might someday help guide treatment of men with prostate cancer, he said. "If the markers are positive, that might be an indication that more aggressive therapy is indicated," Concato said.

However, that claim was challenged in an accompanying editorial by a cancer specialist.

The findings stemmed from an examination of tissue samples from 1,172 men diagnosed with prostate cancer at VA centers in New England. Researchers looked at a number of possible biomarkers and identified three associated with a higher risk of death from the cancer: bcl-2, a molecule that helps regulate cell death; p53, a protein produced by a tumor-suppressor gene; and microvessel density, the excessive production of blood vessels needed for growth of a cancer.

Levels of all three markers were significantly higher in the men who died of prostate cancer in the subsequent 11 to 16 years, the study found.

Concato said the study is just a first step toward use of the biomarkers to guide prostate cancer treatment. "Other groups should replicate our results," he said. "Based on these results, there should be an effort at developing therapies that attack the mechanisms reflected by these markers."

Concato said he has proposed a clinical trial that "would treat patients based on marker status, as positive or negative."

The editorial by Dr. Edward P. Gelmann, chief of the division of hematology/oncology and deputy director of the Herbert Irving Comprehensive Cancer Center at Columbia University, challenged the value of all three biomarkers.

A number of previous studies have shown that results of p53 tests "are not reproducible from one laboratory to the next," Gelmann said. "There is great variability in both technique and results." Though p53 has been studied as a biomarker for a number of cancers, he said, it is used only for one rare malignancy, transitional cell carcinoma of the blood.

As for bcl-2, Gelmann said that the number of cases in the study with a positive reading was too small to provide proof of its predictive power. "To prove it has prognostic significance would require would require a larger trial," he said.

And the measure of blood vessel density done in the study was not necessarily reproducible, Gelmann said. "It was done by an individual observer without anyone else checking it," he said.

In response, Concato said that "the editorial doesn't mention several major strengths of the study, and it misrepresents what was known before we did our study."

"For example, showing a link between markers taken at diagnosis and long-term mortality had not been shown before," he said. "Perhaps the editorial is concerned about inappropriate, excessive use of these markers -- and, if so, we would agree."

More information

The U.S. National Cancer Institute has more on prostate cancer.



SOURCES: John Concato, M.D., professor, medicine, Yale University, and director, Clinical Epidemiological Research Center, Veterans Affairs Connecticut Healthcare System, New Haven, Conn.; Edward P. Gelmann, M.D., chief, division of hematology/oncology, and deputy director, Herbert Irving Comprehensive Cancer Center, Columbia University, New York City; May 5, 2009, Annals of Internal Medicine


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Vitamin D Linked to HDL Cholesterol - Shaklee Corporation Research Links Vitamin D with Key Biomarkers for Metabolic Syndrome and Heart Disease
2. Potential lung disease biomarkers yield clues to COX-2 inhibitor side effects
3. Cordex Pharma to Collaborate with BG Medicine in a Clinical Study of Heart Failure Biomarkers
4. Biomarkers detected for Chikungunya fever
5. Frost & Sullivan Lauds Toscana Biomarkers Outstanding Contributions to the R&D of Novel Biomarkers for the Diagnosis of Autoimmune Diseases
6. Thomson Reuters White Paper Explores the Role of Biomarkers in Clinical Trials and Drug Development
7. Biomarkers improve ischemic stroke prediction
8. Biomarkers: What can they tell us
9. PreMD Files Provisional Patent Application Describing a New Method of Quantifying Cancer Biomarkers
10. Biomarkers May Help Spot, Track Alzheimers
11. Toyota Tsusho America, Inc. and Nippon Kayaku Co., Ltd. Announce the Formation of GlycoMark, Inc., a Joint Venture to Develop and Commercialize Novel Biomarkers for Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Biomarkers May Predict Aggressiveness of Prostate Cancer
(Date:2/19/2017)... Warwick, RI (PRWEB) , ... February 19, 2017 ... ... data is proven to result in better care, and MEDfx and the Delaware ... the state of Delaware. , As the nation’s first state-wide health information exchange, ...
(Date:2/18/2017)... Church, VA (PRWEB) , ... ... ... Culture of Change for Devicemakers , Sponsored by Axendia, **FDAnews Free Webinar**, ... , Are manufacturers looking to reduce their regulatory burden? Pay dividends ...
(Date:2/18/2017)... ... 17, 2017 , ... Butler Mobility invited Ken Matthews to visit its manufacturing ... Ken was impressed with the safety and reliability of the Stannah Stairlift as ... show. This endorsement by Ken Matthews can be heard on News Radio WHP ...
(Date:2/18/2017)... ... ... Park Cities Pet Sitter President, Joette White, has been featured on Episode ... The episode, which was posted this week, features a 30-minute interview of White by ... Pet Sitter’s being awarded the 2017 National Association of Professional Pet Sitter’s Business of ...
(Date:2/18/2017)... ... February 18, 2017 , ... A new directory ... contact points to easily connect elderly veterans of America's armed forces to a ... It also conveys material on this year's increase in the Veterans Pension with ...
Breaking Medicine News(10 mins):
(Date:2/16/2017)... The Lockwood Group (Lockwood), a medical communications agency, was recently ... Connecticut list by the Hartford Business ... that Lockwood has been in the top 10, moving up ... 2017. The award recognizes companies that have been successful in ... a survey conducted by The Best Companies Group that ranked ...
(Date:2/16/2017)... 16, 2017 Summary Provides understanding and ... the worlds leading healthcare companies. ... Description The Global Allergy Partnering Terms and Agreements ... agreements entered into by the world,s leading healthcare companies. ... value - Deals listed by company A-Z, industry sector, stage ...
(Date:2/16/2017)... 2017   Spectralink Corporation , the global ... retail, manufacturing and hospitality industries, today announced the ... symbology support features of its PIVOT™:SC (8744) ... The study, conducted by The Tolly Group, showed ... phones with dedicated hardware scanners. Spectralink ...
Breaking Medicine Technology: